NC
JAZZ icon

NewSquare Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

NewSquare Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-60
Closed -$6.37K – 711
2025
Q2 		$6.37K Sell
60
-4
-6% -$435 ﹤0.01% 753
2025
Q1 		$7.95K Buy
64
+4
+7% +$522 ﹤0.01% 596
2024
Q4 		$7.39K Buy
+60
New +$7.07K ﹤0.01% 308

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

NewSquare Capital's JAZZ Position: Q3 2025 in Review

NewSquare Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2025, closing a stake of 60 shares — an estimated $6.37K sold.

NewSquare Capital first reported a position in JAZZ in Q4 2024 and held it in 3 quarters. The position peaked at $7.95K in Q1 2025. 502 funds tracked by Wall St. Rank hold JAZZ as of Q3 2025.

  • NewSquare Capital reported no remaining Jazz Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • NewSquare Capital sold 60 Jazz Pharmaceuticals shares in Q3 2025, an estimated $6.37K.
  • NewSquare Capital first reported a position in Jazz Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • NewSquare Capital's Jazz Pharmaceuticals position peaked at $7.95K in Q1 2025.
  • 502 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2025.

Based on NewSquare Capital's 13F filing for Q3 2025, filed 12 Nov 2025.